Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579084 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
A Phase 1 study of Rosacea and Erythema, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT01579084: Completed Phase 1 study of Rosacea and Erythema, sponsored by Allergan.
NCT01579084 is a Phase 1 study of Rosacea and Erythema that has completed, run by Allergan. The registered enrollment target is 64 participants, below the 240-participant average among 23 other Rosacea trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01579084, a Phase 1 study of Rosacea and Erythema, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.
Primary Outcome
The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 1. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate er
Interventions
- DRUG AGN-199201 Formulation A
- DRUG AGN-199201 Formulation B
- DRUG AGN-199201 Formulation C
- DRUG AGN-199201 Vehicle
Study Locations (1)
Texas
- - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
What the finished NCT01579084 record still lists
NCT01579084 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 240-participant average among 23 other Rosacea trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Rosacea appearing as the primary indexed condition, and to 4 interventions - of which AGN-199201 Formulation A is the first listed.
NCT01579084 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01579084 about?
NCT01579084 is a clinical study titled "Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea". This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.
What is the current status of trial NCT01579084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2012-04. Estimated completion is 2012-06.
What conditions does trial NCT01579084 study?
This clinical trial studies the following conditions: Rosacea, Erythema.
What interventions are being tested in trial NCT01579084?
The interventions under investigation include: AGN-199201 Formulation A (DRUG), AGN-199201 Formulation B (DRUG), AGN-199201 Formulation C (DRUG), AGN-199201 Vehicle (DRUG).
Who is sponsoring clinical trial NCT01579084?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01579084 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01579084's enrollment target sits among peer trials
64 15th of 23 higher than 9 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
COMPLETED · Phase 1
-
Topical Agent for Treatment of Red Skin
COMPLETED · Phase 1
-
Timolol for the Treatment of Acne and Rosacea
COMPLETED · Phase 1
-
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
COMPLETED · Phase 1
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia